Cargando…

Risks associated with sunitinib use and monitoring to improve patient outcomes

Detalles Bibliográficos
Autor principal:	Choi, Bum Soon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2014
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932391/ https://www.ncbi.nlm.nih.gov/pubmed/24574829 http://dx.doi.org/10.3904/kjim.2014.29.1.23

Ejemplares similares

Sorafenib and sunitinib: A dermatologist's perspective
por: Pragasam, Vijendran, et al.
Publicado: (2014)

Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2012)

Exaggerated Cardiotoxicity of Sunitinib in Stressed 3-Dimensional Heart Muscles
por: Eschenhagen, Thomas
Publicado: (2018)

Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2019)

Validation Study of the Oxford Classification for IgA Nephropathy in Korean Adults
por: Choi, Bum Soon
Publicado: (2012)

Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients
por: Numakura, Kazuyuki, et al.
Publicado: (2018)

Opportunities for Improving Outcomes in Severe Malaria: The Role of Blood Glucose Monitoring
por: Torres-Fernandez, David, et al.
Publicado: (2023)

Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma
por: Zhu, Xudong, et al.
Publicado: (2021)

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
por: Fiala, Ondřej, et al.
Publicado: (2021)

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib
por: Beuselinck, B, et al.
Publicado: (2013)

Statin Therapy to Improve Outcome of COVID-19 Patients: Useful or Not Useful?
por: Mégarbane, Bruno
Publicado: (2022)

Surgery after sunitinib administration to improve survival of patients with advanced pancreatic neuroendocrine neoplasms
por: Murase, Yoshiki, et al.
Publicado: (2021)

Sunitinib Induced Immune Thrombocytopenia
por: Shekarriz, Ramin, et al.
Publicado: (2015)

Sunitinib: the antiangiogenic effects and beyond
por: Hao, Zhonglin, et al.
Publicado: (2016)

Reversal of Cushing Pigmentation by Sunitinib
por: Iwasaki, Yorihiro, et al.
Publicado: (2019)

Sunitinib: Colitis: case report
Publicado: (2022)

Key Factors in Improving Clinical Outcomes in Patients with Cardiac Arrest Undergoing Extracorporeal Cardiopulmonary Resuscitation: a Multidisciplinary Team Approach
por: Cha, Jung-Joon, et al.
Publicado: (2021)

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial
por: Staehler, M, et al.
Publicado: (2018)

Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib
por: Keyvanjah, Kiana, et al.
Publicado: (2012)

Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
por: Keizman, Daniel, et al.
Publicado: (2016)

Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients
por: Liu, Xiaoyan, et al.
Publicado: (2016)

The yin yang of sunitinib: One drug, two doses, and multiple outcomes
por: Elgendy, Mohamed
Publicado: (2017)

Elderly High-Risk Stage II Colorectal Cancer Patients: Candidates for Improving Outcome?
por: Kim, Min Ki
Publicado: (2021)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
por: Ordu, Çetin, et al.
Publicado: (2016)

Strategies to improve outcomes of bronchopulmonary dysplasia
por: Jung, Young Hwa, et al.
Publicado: (2019)

Taking the ‘Risk’ out of risk-based monitoring
por: Gupta, Ashwaria
Publicado: (2013)

What Can Lipids in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Tell Us?
por: Choi, Chan-Bum
Publicado: (2021)

Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma
por: Schwandt, Anita, et al.
Publicado: (2009)

Effect of gastrointestinal resection on sunitinib exposure in patients with GIST
por: de Wit, Djoeke, et al.
Publicado: (2014)

Angiosarcoma of the Retroperitoneum: Report on a Patient Treated with Sunitinib
por: Yoo, Changhoon, et al.
Publicado: (2009)

The complexity of sunitinib dosing in renal cell cancer patients
por: Desar, Ingrid M.E., et al.
Publicado: (2012)

Pneumatosis cystoides intestinalis associated with sunitinib and a literature review
por: Lee, Yong Suk, et al.
Publicado: (2017)

Re: Comparison of immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial
por: Minervini, Andrea, et al.
Publicado: (2019)

Patient-reported outcome measures in a pharmacokinetic study with sunitinib, a prospective cohort study
por: Koldenhof, J. J., et al.
Publicado: (2018)

Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib‐Treated Cancer
por: Diekstra, MH, et al.
Publicado: (2017)

Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib
por: Fazio, Nicola, et al.
Publicado: (2021)

Sunitinib resistance in renal cell carcinoma
por: Morais, Christudas
Publicado: (2014)

Sunitinib for advanced renal cell cancer
por: Coppin, Chris
Publicado: (2008)

Combining radiotherapy with sunitinib: lessons (to be) learned
por: Kleibeuker, Esther A., et al.
Publicado: (2015)

Sunitinib-Induced Acute Liver Failure
por: Aqsa, Anum, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ui9dfvoe03jtvtp44onje6n7hb